Pay in 4 interest-free payments of $5.55 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Innovation 5 , 100722 (2024)
DESTINY-Lung01, a phase II trial evaluating the efficacy of T-DXd in pre-treated NSCLC harboring HER2 molecular alterations includes two cohorts of patients: The HER2 -mutant cohort included 91 patients, showing an ORR of 55%, a median DoR of 9.3 months (95% CI, 5.7 to 14.7) and medians PFS and OS of 8.2 (95% CI, 6.0 to 11.9) and 17.8 months (95% CI, 13.8 to 22.1), respectively [4,33,34]
(If no, stay at current dose) Are my side effects mild or absent
Asia-Pacific (including Japan) - Strongest growth region supported by rising diabetic population, expanding healthcare access, increasing awareness, and large-scale pharmaceutical manufacturing in China, India, and Southeast Asia, along with Japan's advanced diabetes care ecosystem
